Comparison of hepatosteatosis in mice treated with two forms of asparaginase: Orgel and Mittelman

Calaspargase-pegol (SC-PEG) has replaced pegaspargase (SS-PEG) in pediatric ALL regimens in the United States. Calaspargase-pegol’s greater drug exposure has raised concern for correspondingly increased hepatotoxicity.  However, we found no difference in hepatosteatosis between formulations in obese and non-obese asparaginase-treated mice. These reassuring findings should be confirmed in clinical studies.

Methods
Mice were treated with drug or vehicle. Body weights were recorded by date. At sacrifice, liver was photographed in situ and images are included as jpeg files. Liver weights were recorded. Livers were fixed for histology, and representative histological images are included as png files. Histological scoring was done by a pathologist and are recorded. Plasma chemistries were measured and recorded.